[go: up one dir, main page]

FI962800A - Fenylheterocykliska föreningar som COX-2 inhibitorer - Google Patents

Fenylheterocykliska föreningar som COX-2 inhibitorer Download PDF

Info

Publication number
FI962800A
FI962800A FI962800A FI962800A FI962800A FI 962800 A FI962800 A FI 962800A FI 962800 A FI962800 A FI 962800A FI 962800 A FI962800 A FI 962800A FI 962800 A FI962800 A FI 962800A
Authority
FI
Finland
Prior art keywords
cox
inhibitors
heterocyclic compounds
phenyl heterocyclic
phenyl
Prior art date
Application number
FI962800A
Other languages
English (en)
Finnish (fi)
Other versions
FI108792B (sv
FI962800A0 (sv
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wand
Serge Leger
Michael Laval Therien
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of FI962800A0 publication Critical patent/FI962800A0/sv
Publication of FI962800A publication Critical patent/FI962800A/sv
Application granted granted Critical
Publication of FI108792B publication Critical patent/FI108792B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
FI962800A 1994-01-10 1996-07-09 Förfarande för framställning av nya, terapeutiskt anvädbara furanonderivat FI108792B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17946794 1994-01-10
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors
CA9400688 1994-12-19
PCT/CA1994/000688 WO1995018799A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors

Publications (3)

Publication Number Publication Date
FI962800A0 FI962800A0 (sv) 1996-07-09
FI962800A true FI962800A (sv) 1996-09-06
FI108792B FI108792B (sv) 2002-03-28

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962800A FI108792B (sv) 1994-01-10 1996-07-09 Förfarande för framställning av nya, terapeutiskt anvädbara furanonderivat

Country Status (12)

Country Link
EP (1) EP0739340A1 (sv)
JP (1) JP2788677B2 (sv)
CN (1) CN1143365A (sv)
AU (1) AU1269495A (sv)
BG (1) BG63082B1 (sv)
BR (1) BR9408478A (sv)
CA (1) CA2180651A1 (sv)
FI (1) FI108792B (sv)
HU (1) HUT74986A (sv)
NO (1) NO960393L (sv)
SG (1) SG43841A1 (sv)
WO (1) WO1995018799A1 (sv)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
HU225506B1 (en) * 1995-07-19 2007-01-29 Merck & Co Inc Use of 4-(4-methylsulfonyl-phenyl)-3-phenyl-2-(5h)-furanone for the preparation of medicaments treating colonic adenomas
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
SK284330B6 (sk) * 1996-05-17 2005-01-03 Merck & Co., Inc. Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6136831A (en) * 1997-04-11 2000-10-24 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and COX inhibitors containing them
AU7237998A (en) * 1997-05-16 1998-12-08 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
ES2231757T3 (es) 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
CA2484897C (en) 2002-05-09 2015-10-06 The Brigham And Women's Hospital, Inc. Soluble st2 as a cardiovascular disease marker and therapeutic target
US7087630B2 (en) 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
KR20050051729A (ko) * 2003-11-28 2005-06-02 일양약품주식회사 사이클로 옥시게나제-2 억제제인 페닐 헤테로사이클의제조방법
DE102004027912A1 (de) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
WO2006042192A2 (en) 2004-10-06 2006-04-20 The Brigham And Womens's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
EP2174658A1 (en) 2005-05-31 2010-04-14 Mylan Laboratories, Inc Compositions comprising nebivolol
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
DK2001496T3 (en) 2006-03-15 2017-09-18 Brigham & Womens Hospital Inc USE OF GELSOLIN FOR DIAGNOSTICATION AND TREATMENT OF INFLAMMATION DISEASES
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
TW200849035A (en) 2007-04-18 2008-12-16 Tethys Bioscience Inc Diabetes-related biomarkers and methods of use thereof
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
JP2013518618A (ja) 2010-02-01 2013-05-23 ザ・ホスピタル・フォー・シック・チルドレン 再狭窄を治療および予防するための遠隔虚血コンディショニング
KR20190000368A (ko) 2010-03-31 2019-01-02 더 호스피탈 포 식 칠드런 심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
SG11201407402TA (en) 2012-05-11 2014-12-30 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
EP3853305B1 (en) 2018-09-19 2024-10-02 ModernaTX, Inc. High-purity peg lipids and uses thereof
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388909A3 (en) * 1989-03-22 1991-05-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
JPH05506215A (ja) * 1990-04-17 1993-09-16 アラーガン、インコーポレイテッド 抗炎症剤としての５および／または４位で置換した２（５ｈ）―フラノン
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
CA2297592A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0714391A1 (en) * 1993-08-19 1996-06-05 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists

Also Published As

Publication number Publication date
HU9601875D0 (en) 1996-09-30
JP2788677B2 (ja) 1998-08-20
CN1143365A (zh) 1997-02-19
BG63082B1 (bg) 2001-03-30
SG43841A1 (en) 1997-11-14
AU1269495A (en) 1995-08-01
FI108792B (sv) 2002-03-28
JPH09506631A (ja) 1997-06-30
FI962800A0 (sv) 1996-07-09
NO960393D0 (no) 1996-01-30
BR9408478A (pt) 1997-08-26
EP0739340A1 (en) 1996-10-30
BG100350A (bg) 1996-12-31
NO960393L (no) 1996-07-09
HUT74986A (en) 1997-03-28
CA2180651A1 (en) 1995-07-13
WO1995018799A1 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
FI962800A (sv) Fenylheterocykliska föreningar som COX-2 inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
ATE231132T1 (de) Heterocyclische metalloprotease inhibitoren
EE200000031A (et) Uued spiroasabitsüklilised heterotsüklilised ühendid
ATE226573T1 (de) Heterozyklische metalloproteaseinhibitoren
DK1100797T3 (da) Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
EE9900259A (et) Ühendi uus vorm
FI971104A (sv) Förfarande för framställning av fenylheterocykler användbara som COX-inhibitorer
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
PT907650E (pt) N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
FI990922A (sv) Nya föreningar
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
DK0820451T3 (da) Hidtil ukendte heterocykliske forbindelser
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE69903319D1 (de) Fkbp inhibitoren
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
NO993161D0 (no) Cyklooksygenaseinhibitor
NO995430D0 (no) Nye heterosykliske forbindelser
FI963509A (sv) Isoxazolinföreningar som 5-lipoxigenasinhibitorer
FI941265A (sv) Heterocykliska sulfonamidotrombininhibitorer
ID18481A (id) 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2
SE9402122D0 (sv) Heterocyclic compounds

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: MERCK FROSST CANADA & CO.

PC Transfer of assignment of patent

Owner name: MERCK FROSST COMPANY

Free format text: MERCK FROSST COMPANY

MM Patent lapsed